Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Feb 3;148(2):354-356.
doi: 10.1093/brain/awaf007.

Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified

Sofia Toniolo  1   2
Affiliations
Editorial

Which plasma pTau217 assay should I use in clinical practice? Pandora's box demystified

Sofia Toniolo. Brain. .

Abstract

This scientific commentary refers to ‘A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests’ by Warmenhoven et al. (https://doi.org/10.1093/brain/awae346) and ‘Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison’ by Pilotto et al. (https://doi.org/10.1093/brain/awae368).

PubMed Disclaimer

Conflict of interest statement

The author reports no competing interests.

Comment on

  • A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
    Warmenhoven N, Salvadó G, Janelidze S, Mattsson-Carlgren N, Bali D, Orduña Dolado A, Kolb H, Triana-Baltzer G, Barthélemy NR, Schindler SE, Aschenbrenner AJ, Raji CA, Benzinger TLS, Morris JC, Ibanez L, Timsina J, Cruchaga C, Bateman RJ, Ashton N, Arslan B, Zetterberg H, Blennow K, Pichet Binette A, Hansson O. Warmenhoven N, et al. Brain. 2025 Feb 3;148(2):416-431. doi: 10.1093/brain/awae346. Brain. 2025. PMID: 39468767 Free PMC article.
  • Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
    Pilotto A, Quaresima V, Trasciatti C, Tolassi C, Bertoli D, Mordenti C, Galli A, Rizzardi A, Caratozzolo S, Zancanaro A, Contador J, Hansson O, Palmqvist S, De Santis G, Zetterberg H, Blennow K, Brugnoni D, Suárez-Calvet M, Ashton NJ, Padovani A. Pilotto A, et al. Brain. 2025 Feb 3;148(2):408-415. doi: 10.1093/brain/awae368. Brain. 2025. PMID: 39679606 Free PMC article.

References

    1. Teunissen CE, Kolster R, Triana-Baltzer G, Janelidze S, Zetterberg H, Kolb HC. Plasma p-tau immunoassays in clinical research for Alzheimer’s disease. Alzheimer’s Dement. Published online 3 December 2024. doi:10.1002/alz.14397 - DOI - PMC - PubMed
    1. Warmenhoven N, Salvadó G, Janelidze S, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025;148:416–431. - PMC - PubMed
    1. Pilotto A, Quaresima V, Trasciatti C, et al. Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain. 2025;148:408–415. - PMC - PubMed
    1. Feng W, Beer JC, Hao Q, et al. NULISA: A proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14:7238. - PMC - PubMed
    1. Musso G, Cosma C, Zaninotto M, Gabelli C, Basso D, Plebani M. Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease. Clin Chem Lab Med. 2022;61:E53–E56. - PubMed

LinkOut - more resources